Correction to: Clinical usefulness of eribulin as first- or second-line chemotherapy for recurrent HER2-negative breast cancer: a randomized phase II study (JBCRG-19)

Source: International Journal of Clinical Oncology - Category: Cancer & Oncology Source Type: research